CCL19 and atherosclerosis: Decreased levels of CCL19 -- a homeostatic interferon-regulated chemokine that binds to CCR7 and plays a role in recruiting T-cells and dendritic cells to target organs, promoting inflammatory responses, and unstable plaque formation in atherosclerosis [36] -- were present in mice treated with L-4F compared to control mice (Figure 6c).